Purchase Order 19CM8026P0234
- Not listed
- <p>This is a firm fixed-price purchase order for the delivery of MALARONE anti-malaria medication from Nairobi, Kenya. The $74,087 contract was awarded by the Bureau of African Affairs, a civilian agency within the U.S. Department of State, to Miscellaneous Foreign Awardees, a for-profit organization, with a period of performance ending on December 25, 2024. The contract is not designated as a set-aside. No subcontractors are mentioned in the information provided.</p>
- The Department of State Bureau of African Affairs awarded a $46,006.89 firm fixed price purchase order to Miscellaneous Foreign Awardees for the urgent delivery of Malarone adult medication from Kenya to Kinshasa, Democratic Republic of the Congo. The prime contractor will provide the antimalarial drugs under the contract, which runs from September 27, 2023 through October 18, 2023. The funding supports the Department of State's efforts to address urgent public health needs in the Democratic...
- The U.S. Department of State's Bureau of African Affairs awarded a $25,315 firm fixed-price purchase order to Miscellaneous Foreign Awardees for the supply of atovaquone/proguanil, an antimalarial pharmaceutical combination commonly used for malaria prevention and treatment. The award was issued on January 29, 2026, with performance scheduled to conclude by February 27, 2026, and will be delivered to Uganda. This contract represents a straightforward procurement of medical supplies to support...
- This is a firm fixed-price purchase order awarded by the Bureau of African Affairs, a civilian agency within the U.S. Department of State, to Miscellaneous Foreign Awardees (Ipte, LLC) for the annual procurement of Malarone malaria medications in Kenya. The award value is $16,464.00 and the ultimate completion date is February 27, 2025. There is no set-aside designation for this contract. Ipte, LLC is a global supplier of automation and test engineering solutions that holds multiple...
- This is a $8,058.96 fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The order is for MALARONE 250/100 100S, a malaria medication, under an existing Indefinite Delivery Contract (IDC) valued at $999,999,999 with DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Malarone 250-100 mg tablets (100 count) with a contract value of $3,182.62. This is a firm fixed-price delivery order with no set-aside designation, executed as a competitive award. The order is scheduled for completion by September 29, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The contract is a delivery order valued at $7,849.91 for the supply of Atovaquone-Proguanil 250-100 100s, a medication used for malaria prevention and treatment. The award is not designated as a set-aside contract. It is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,278.26 firm fixed-price delivery order is for 4,556,383,444 units of Malarone 250-100 mg tablets, which are used to prevent and treat malaria. The contract has a period of performance through February 28, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is registered...
- The Defense Logistics Agency awarded a delivery order valued at $1,117.35 to AmerisourceBergen Drug Corp for Atovaquone-Proguanil 250-100mg tablets (100 count) with an ultimate completion date of August 25, 2025. This firm fixed price, non-set-aside contract was awarded on August 22, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The antimalarial medication will support federal medical supply requirements, likely for military personnel...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $112,825.44 Firm Fixed Price Delivery Order is for the supply of Atovaquone-Proguanil 250-100 100s, a medication used for the prevention and treatment of malaria. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, which...
The U.S. Department of State's Bureau of African Affairs awarded a firm fixed-price purchase order to Orion Pharmacy LTD for the procurement of Malarone tablets (atovaquone-proguanil) for the Yaounde Adult program in Kenya. The contract, valued at $29,872.76, was awarded on February 20, 2026, with an ultimate completion date of March 30, 2026. This award represents a civilian agency acquisition with no set-aside designation applied to the procurement. Malarone tablets are antimalarial medications commonly used for malaria prevention and treatment in endemic regions. This procurement supports the State Department's public health initiatives in Africa, likely providing medical supplies to support U.S. diplomatic personnel, exchange program participants, or public health assistance activities in the East Africa region. The relatively modest contract value and compressed performance timeline suggest this is a targeted procurement to fulfill an immediate or ongoing operational medical supply requirement in Kenya.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $29.9k | 2/19/26 |